Artificial Intelligence Assisted Pharmacophore Design for Philadelphia Chromosome-Positive Leukemia with Gamma-Tocotrienol: A Toxicity Comparison Approach with Asciminib
暂无分享,去创建一个
Namrah Zafar | A. Alasmari | M. Alharbi | M. Naveed | T. Aziz | K. Javed | M. A. Shabbir | A. Alsahammari
[1] S. Sy,et al. Exposure–Efficacy Analysis of Asciminib in Philadelphia Chromosome–Positive Chronic Myeloid Leukemia in Chronic Phase , 2022, Clinical pharmacology and therapeutics.
[2] S. Sy,et al. Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases , 2022, Clinical Pharmacokinetics.
[3] M. Mathai,et al. Revisiting the therapeutic potential of tocotrienol , 2022, BioFactors.
[4] R. Pappu,et al. AlphaFold and implications for intrinsically disordered proteins. , 2021, Journal of molecular biology.
[5] M. Bonifacio,et al. Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy , 2021, PharmacoEconomics - Open.
[6] Junzhou Huang,et al. WADDAICA: A webserver for aiding protein drug design by artificial intelligence and classical algorithm , 2021, Computational and structural biotechnology journal.
[7] J. Cortes,et al. Third-line therapy for chronic myeloid leukemia: current status and future directions , 2021, Journal of Hematology & Oncology.
[8] J. Abdul-Ghafar,et al. Philadelphia chromosome positive chronic myeloid leukemia with 5q deletion at diagnosis , 2021, Molecular Cytogenetics.
[9] S. Cowan-Jacob,et al. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. , 2020, Leukemia research.
[10] P. le Coutre,et al. Early molecular response in East African Philadelphia chromosome-positive chronic myeloid leukaemia patients treated with Imatinib and barriers to access treatment , 2020, Ecancermedicalscience.
[11] Jerzy Leszczynski,et al. Open access in silico tools to predict the ADMET profiling of drug candidates , 2020, Expert opinion on drug discovery.
[12] A. Baruchel,et al. Ponatinib in childhood Philadelphia chromosome-positive leukaemias: an international registry of childhood chronic myeloid leukaemia study. , 2020, European journal of cancer.
[13] H. Kantarjian,et al. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring , 2020, American journal of hematology.
[14] Tiziano Tuccinardi,et al. Application of MM-PBSA Methods in Virtual Screening , 2020, Molecules.
[15] Y. Mabkhot,et al. Petra/Osiris/Molinspiration and Molecular Docking Analyses of 3-Hydroxy-Indolin-2-one Derivatives as Potential Antiviral Agents. , 2019, Current computer-aided drug design.
[16] K. Yoo,et al. Phase 2 Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia. , 2019, Blood.
[17] Mario Medvedovic,et al. Cheminformatics Tools for Analyzing and Designing Optimized Small-Molecule Collections and Libraries. , 2019, Cell chemical biology.
[18] K. Chin,et al. The Role of Tocotrienol in Protecting Against Metabolic Diseases , 2019, Molecules.
[19] O. Ayyıldız,et al. Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome–positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-up , 2018, Hematology.
[20] Andreas Eckert,et al. ProTox-II: a webserver for the prediction of toxicity of chemicals , 2018, Nucleic Acids Res..
[21] Gianni De Fabritiis,et al. DeepSite: protein‐binding site predictor using 3D‐convolutional neural networks , 2017, Bioinform..
[22] Paul W Dickman,et al. Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Eduardo Krempser,et al. DockThor 2 . 0 : a Free Web Server for Protein-Ligand Virtual Screening , 2017 .